Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE Medical

This article was originally published in The Gray Sheet

Executive Summary

Shareholders of Madison, Wisconsin-based Lunar Corp. will receive 0.322 shares of GE stock for each share of Lunar stock under terms of the firms' merger deal completed Aug. 8. Announced June 2, the agreement was valued at roughly $144 mil. A manufacturer of diagnostics for osteoporosis and metabolic bone disease as well as orthopedic surgery devices, Lunar will add $91 mil. in annual revenues to GE's $7 bil. Medical Systems business. GEMS hopes to accelerate Lunar's top-line growth above the single-digit pace of the overall bone densitometry market (1"The Gray Sheet" June 5, p. 13)
Advertisement

Related Content

GEMS Shooting At Moon In Women's Health Via Lunar Densitometry Buy
GEMS Shooting At Moon In Women's Health Via Lunar Densitometry Buy
Advertisement
UsernamePublicRestriction

Register

MT013726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel